ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

ERAS vs PTCT // 10Y YIELD & FRED MACRO BETA

Erasca Inc. (NASDAQ) VS. PTC Therapeutics Inc. (NASDAQ) • 15-METRIC TALLY: ERAS 2 — PTCT 3
■ METRIC PARITY
macro-sensitivity
—
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (ERAS VS. PTCT) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC ERAS PTCT SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin — — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) -35.00% 85.00% -120.00 PTCT /roic <GO>
EV/EBITDA & P/E Valuation — 6.5x — TIE /valuation <GO>
Free Cash Flow Yield -1.82% 13.05% -14.87 PTCT /fcf-yield <GO>
Operating Margin — 50.10% — TIE /operating-margins <GO>
Net Profit Margin — 39.50% — TIE /net-margins <GO>
Revenue Growth (YoY) — 114.50% — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — 1.73 — TIE /balance-sheet <GO>
Piotroski F-Score Quality 3/9 9/9 -6.00 PTCT /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 45.3 43.2 +2.10 ERAS /rsi-technicals <GO>
10Y Yield & FRED Macro Beta ACTIVE — 1.15 — TIE /macro-sensitivity <GO>
Forward P/E Multiple — 6.6x — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $5.02B $5.01B $8.9M ERAS /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR ERAS REV PTCT REV ERAS GROSS % PTCT GROSS % ERAS FCF PTCT FCF
FY 2025 $394.5M $1.73B — — -$95.6M $702.3M
FY 2024 $502.8M $806.8M — — -$109.5M -$114.2M
FY 2023 $396.3M $937.8M — — -$101.2M -$200.6M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
ERAS // BETA —
PTCT // BETA 1.15